Drug Trial Radar · NCT04169503
Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events
Last checked: Nov 20, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
17,562
Planned (sponsor's estimate)
Start
Oct 14, 2019
Primary completion
Jan 2020
Study completion Feb 2020
Sponsor
- Lead sponsor
- University Hospital, CaenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE. Our objective was to investigate the safety of ICI rechallenge after an irAE using the WHO pharmacovigilance database
Conditions
- Cancer
Interventions
Immune Checkpoint ModulatorDrug
identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of occurrence of second immune-related adverse events (irAEs)Time frame: Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexandre Joachim
Caen, Basse Normandie, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.